ArticleCell death and differentiation2026
Histone arginine demethylase JMJD7 promotes bone formation through regulating α-Ketoglutarate metabolism.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Histone methylation plays a critical role in chromatin accessibility and transcription regulation, with implications for various disorders, including osteoporosis. Jumonji C domain-containing protein 7 (JMJD7) demethylates arginine (R) residues on histones, influencing tissue metabolism and integrity. However, its role in bone tissue remains uncharacterized. We have discovered JMJD7 loss in human osteoporotic bone biopsies, and neonatal osteoblast-specific Jmjd7 knockout mice exhibit delayed cranial suture closure and premature mortality. Adult female Jmjd7 knockout mice, but not males, develop a smaller stature with hallmark features of osteoporosis and visceral adiposity. Forced Jmjd7 expression mitigates estrogen deficiency-induced bone loss. Jmjd7 deletion alters the transcriptomic landscape and promotes the H3R2me1-enriched epigenome, particularly affecting cellular energy metabolism and suppressing osteogenic differentiation of bone marrow mesenchymal cells. Runx2 is, among others, a functional epigenomic target of Jmjd7. Mechanistically, Jmjd7 loss disrupts energy production by shifting towards anaerobic glycolysis at the expense of mitochondrial oxidative phosphorylation. This metabolic shift is mediated through inhibition of complex I activity and reduced production of isocitrate dehydrogenase (Idh) and its intermediate α-ketoglutarate (α-KG). Notably, α-KG supplementation reverses H3R2me1-dependent transcriptional repression and mitigates post-translational arginine methylation and ubiquitination of Idh and Runx2, counteracting Jmjd7 deletion-induced loss of mineralized matrix synthesis. Furthermore, α-KG supplementation improves osteogenic differentiation and bone formation, attenuating both Jmjd7 loss- and estrogen deficiency-induced osteoporosis. Taken together, Jmjd7 is indispensable for bone integrity, and its loss accelerates osteoporosis through epigenetic repression of α-KG production, affecting mitochondrial energy metabolism and Runx2 signaling. This study reveals a novel anabolic function of Jmjd7 in maintaining bone mass homeostasis and emphasizes the essential role of its cofactor α-KG in promoting bone health.
Identifiers
41922800What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.